Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Massive canadian study tracks dialysis switches to improve patient care

NCT ID NCT07477210

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses health records from 17,000 Canadian adults to understand why some people switch from peritoneal dialysis (done at home) to hemodialysis (done in a clinic). Researchers will look at how often this happens, what predicts it, and what happens to patients after the switch, such as hospital stays or survival. The goal is to help doctors and patients plan better care during these transitions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 17,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2005

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults initiating dialysis in Canada between 2005 and 2018 who received peritoneal dialysis for at least 30 consecutive days, identified using the Canadian Organ Replacement Register (CORR) and linked administrative databases.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years) * Dialysis initiation in Canada between January 1, 2005 and December 31, 2018 * Peritoneal dialysis duration \>30 consecutive days Exclusion Criteria: * Dialysis initiation in Quebec or Manitoba during the study period * Dialysis initiation in a foreign country * Missing data on initial dialysis modality * Pre-emptive kidney transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CIUSSS de l'Est-de-l'ile de Montréal

    Montreal, Quebec, H1T 2M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.